A treatment pathway for patients with a confirmed diagnosis of EoE. Different case severities are taken into consideration. UK–2300075
A slide set covering the data behind food bolus obstruction highlighting that this can often be the first presentation related to EoE in patients. It covers the incidence, management and follow-up.
A slide set which provides a detailed background of EoE, including average diagnostic rates.
A set of slides describing the pathological features of EoE. There is a focus on distinguishing between EoE and gastro-oesophageal reflux disease (GORD).
A slide set explaining how endoscopy is critical in EoE diagnosis, especially in obtaining biopsies. Images of EoE features are included, with a method for grading severity.
A slide set presenting evidence from the pivotal Jorveza studies. They cover both the induction of remission, and maintenance.
A slide set highlighting the Jorveza maintenance study data.
A slide set which summarise the EoE guidelines written in 2022 by the BSG/BSPGHAN group.
An overview document summarising the EoE guidelines written in 2022 by the BSG/BSPGHAN group.
The BSG/BSPGHAN guidelines and statements on EoE including its presentation, diagnosis, investigation, management and complications.
A paper which provides an evaluation of topical steroids for treating EoE, especially budesonide oral dispersible (Jorveza) efficacy and safety.
A study which explores the effect of a gap in care for EoE patients. The gap is defined as two years or longer and was associated with signs of increased disease activity.
A study exploring the efficacy of Jorveza as induction therapy for EoE. The study followed 88 adults over 12 weeks, and found that 85% of patients treated with BOT reached complete remission over this time.
A study exploring the efficacy of Jorveza as maintenance therapy among EoE patients. Up to 75% of patients receiving Jorveza remained in remission, compared to 4.4% in the placebo group.
